Stock analysts at Oppenheimer started coverage on shares of PolyPid (NASDAQ:PYPD – Get Free Report) in a report issued on Tuesday, Briefing.com reports. The brokerage set an “outperform” rating and a $10.00 price target on the stock. Oppenheimer‘s price objective would indicate a potential upside of 89.04% from the stock’s current price.
Several other equities analysts have also commented on the stock. Craig Hallum set a $12.00 target price on shares of PolyPid in a report on Wednesday, July 22nd. HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of PolyPid in a research report on Tuesday, July 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PolyPid in a research report on Friday, September 18th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, PolyPid currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.
Check Out Our Latest Analysis on PolyPid
PolyPid Stock Up 0.8%
Shares of NASDAQ:PYPD opened at $5.29 on Tuesday. PolyPid has a twelve month low of $3.40 and a twelve month high of $5.73. The firm has a market capitalization of $100.93 million, a PE ratio of -3.57 and a beta of 1.38. The company has a 50-day moving average price of $5.13 and a two-hundred day moving average price of $4.71.
PolyPid (NASDAQ:PYPD – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03. Analysts anticipate that PolyPid will post -0.92 earnings per share for the current fiscal year.
Institutional Investors Weigh In On PolyPid
Several institutional investors have recently modified their holdings of PYPD. B. Riley Wealth Advisors Inc. grew its position in PolyPid by 32.7% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 20,085 shares of the company’s stock valued at $106,000 after acquiring an additional 4,955 shares during the last quarter. Connective Capital Management LLC purchased a new position in PolyPid during the 2nd quarter worth $343,000. HighTower Advisors LLC purchased a new position in PolyPid during the 2nd quarter worth $56,000. AXQ Capital LP purchased a new stake in shares of PolyPid in the 2nd quarter worth $87,000. Finally, Symmetry Peak Management LLC bought a new position in PolyPid during the 2nd quarter worth about $512,000. 26.47% of the stock is owned by institutional investors.
About PolyPid
PolyPid Ltd. (NASDAQ: PYPD) is a clinical-stage biopharmaceutical company focused on developing locally administered therapies designed to provide controlled and sustained drug release at treatment sites. The company’s technology is intended to maintain therapeutic drug concentrations over extended periods while limiting systemic exposure.
PolyPid’s lead product candidate is D-PLEX100, an investigational formulation based on doxycycline and the company’s proprietary PLEX polymeric matrix.
Read More
- Five stocks we like better than PolyPid
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
